Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin

Clinical Pharmacology in Drug Development

Volumn 1, Issue 1, 2012, Pages 32-37

  Korth Bradley, Joan M ^a   Parks, Virginia ^a   Patat, Alain ^b,d   Matschke, Kyle ^a   Mayer, Philip ^a   Fleckenstein, Lawrence ^c  

^a PFIZER INC   (United States)

^b Clinical Research and Development   (France)

^c UNIVERSITY OF IOWA   (United States)

^d Biotrial   (France)

Author keywords

antiparasitic; bioavailability; moxidectin; onchocerciasis; pharmacokinetics

Indexed keywords

MOXIDECTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG SAFETY; EYE PAIN; FLU LIKE SYNDROME; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INFECTION; INJECTION SITE EDEMA; INJECTION SITE PAIN; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MYALGIA; NORMAL HUMAN; OPEN STUDY; PAIN; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TINNITUS;

EID: 84892093412     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1177/2160763X11432508     Document Type: Article

References (17)

1. Plaisier AP,van Oortmarssen GJ,Remme J,Habbema JD.The reproductive lifespan of Onchocerca volvulus in West African savanna.Acta Trop. 1991;48:271-284.
2. Burnham G.Onchocerciasis.Lancet. 1998;351:1341-1346.
3. World Health Organization. Working to overcome the global impact of neglected tropical diseases: update to WHO report on neglected tropical diseases. 2011. http://www.who.int/neglected_diseases/2010report/WHO_NTD_report_update_2011.pdf. Accessed October 16, 2011.
4. African Programme for Onchocerciasis Control. Final communiqué of the 11th session of the Joint Action Forum of APOC, Paris, France, 6-9 December 2005. Ouagadougou (Burkina Faso). 2005. http://www.who.int/apoc/about/structure/jaf/jaf11_final_communique.pdf. Accessed November 8, 2010.
5. Onchocerciasis and Its Control: Report of a WHO Expert Committee on Onchocerciasis Control. WHO Technical Report Series, Number 852. Geneva, Switzerland: World Health Organization; 1995:.
6. Basanez MG,Pion SD,Churcher TS,Breitling LP,Little MP,Boussinesq M.River blindness: a success story under threat?.PLoS Med. 2006;3:e371.
7. Evans TG.Socioeconomic consequences of blinding onchocerciasis in West Africa.Bull World Health Organ. 1995;73:495-506.
8. Remme JHF.Research for control: the onchocerciasis experience.Trop Med Int Health. 2004;9:243-254.
9. Vlassoff C,Weiss M,Ovuga EB, et al.Gender and the stigma of onchocercal skin disease in Africa.Soc Sci Med. 2000;50:1353-1368.
10. Basanez MG,Pion SD,Boakes E,Filipe JA,Churcher TS,Boussinesq M.Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis.Lancet Infect Dis. 2008;8:310-322.
11. Tagboto SK,Townson S.Onchocerca volvulus and O. lienalis: the microfilaricidal activity of moxidectin compared with that of ivermectin in vitro and in vivo.Ann Trop Med Parasitol. 1996;90:497-505.
12. Cully DF,Vassilatis DK,Liu KK, et al.Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans.Nature. 1994;371:707-711.
13. Forrester SG,Prichard RK,Beech RN.A glutamate-gated chloride channel subunit from Haemonchus contortus: expression in a mammalian cell line, ligand binding, and modulation of anthelmintic binding by glutamate.Biochem Pharmacol. 2002;63:1061-1068.
14. Zulalian J,Stout SJ,da Cunha AR,Garces T,Miller P.Absorption, tissue distribution, metabolism, and excretion of moxidectin in cattle.J Agric Food Chem. 1994;42:381-387.
15. Wu CY,Benet LZ.Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system.Pharm Res. 2005;22:11-23.
16. Cotreau MM,Warren S,Ryan JL, et al.The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans.J Clin Pharmacol. 2003;43:1108-1115.
17. Chen YC,Hung YP,Fleckenstein L.Liquid chromatographic assay of moxidectin in human plasma for application to pharmacokinetic studies.J Pharm Biomed Anal. 2002;29:917-926.